New developments in the antiviral treatment of hepatitis C

被引：10
作者：
de Bruijne, J. [1 ]
Weegink, C. J. [1 ]
Jansen, P. L. M. [1 ]
Reesink, H. W. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, AMC Liver Ctr, NL-1105 AZ Amsterdam, Netherlands
来源：
VOX SANGUINIS | 2009年 / 97卷 / 01期
关键词：
PROTEASE INHIBITOR; PEGINTERFERON ALPHA-2A; INITIAL TREATMENT; VIRAL-HEPATITIS; PLUS RIBAVIRIN; DOUBLE-BLIND; VIRUS; COMBINATION; INTERFERON-ALPHA-2B; EPIDEMIOLOGY;
D O I：
10.1111/j.1423-0410.2009.01187.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Recently, reliable in vitro culture systems have been developed which accelerated antiviral therapy research. Many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are evaluated in clinical trials. These new antiviral agents are expected to improve treatment significantly with potentially shorter treatment duration. The most promising antiviral agents will be reviewed.
引用
收藏
页码：1 / 12
页数：12
相关论文
共 52 条
  • [1] ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME
    CHOO, QL
    KUO, G
    WEINER, AJ
    OVERBY, LR
    BRADLEY, DW
    HOUGHTON, M
    [J]. SCIENCE, 1989, 244 (4902) : 359 - 362
  • [2] A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
    Davis, GL
    Nelson, DR
    Terrault, N
    Pruett, TL
    Schiano, TD
    Fletcher, CV
    Sapan, CV
    Riser, LN
    Li, YF
    Whitley, RJ
    Gnann, JW
    [J]. LIVER TRANSPLANTATION, 2005, 11 (08) : 941 - 949
  • [3] The changing epidemiology of hepatitis C virus infection in Europe
    Esteban, Juan I.
    Sauleda, Silvia
    Quer, Josep
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 (01) : 148 - 162
  • [4] Mechanism of action of interferon and ribavirin in treatment of hepatitis C
    Feld, JJ
    Hoofnagle, JH
    [J]. NATURE, 2005, 436 (7053) : 967 - 972
  • [5] FLISIAK R, 2008, 41 ANN M EUR ASS STU
  • [6] The cyclophilin inhibitor debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
    Flisiak, Robert
    Horban, Andrzej
    Gallay, Philippe
    Bobardt, Michael
    Selvarajah, Suganya
    Wiercinska-Drapalo, Alicja
    Siwak, Ewa
    Cielniak, Iwona
    Higersberger, Jozef
    Kierkus, Jarek
    Aeschlimann, Christian
    Grosgurin, Pierre
    Nicolas-Metral, Valerie
    Dumont, Jean-Maurice
    Porchet, Herve
    Crabbe, Raf
    Scalfaro, Pietro
    [J]. HEPATOLOGY, 2008, 47 (03) : 817 - 826
  • [7] Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Forestier, Nicole
    Reesink, Hendrik W.
    Weegink, Christine J.
    McNair, Lindsay
    Kieffer, Tara L.
    Chu, Hui-May
    Purdy, Susan
    Jansen, Peter L. M.
    Zeuzem, Stefan
    [J]. HEPATOLOGY, 2007, 46 (03) : 640 - 648
  • [8] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [9] GANE E, 2008, 59 ANN M AM ASS STUD
  • [10] Virological response and safety outcomes in therapy-ndive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study
    Gish, Robert G.
    Arora, Sanjeev
    Reddy, K. Rajender
    Nelson, David R.
    O'Brien, Christopher
    Xu, Yi
    Murphy, Brian
    [J]. JOURNAL OF HEPATOLOGY, 2007, 47 (01) : 51 - 59
123456